Médecine

Paramédical

Autres domaines


S'abonner

Methyldibromoglutaronitrile (Euxyl K400): A new and important sensitizer in the United States? - 09/09/11

Doi : 10.1016/S0190-9622(98)70589-4 
J.Mark Jackson, MD, Joseph F. Fowler, MD
University of Louisville, Division of Dermatology. Louisville, Kentucky 

Abstract

Background: Methyldibromoglutaronitrile (MDGN) is a component of Euxyl K400, a preservative used in many skin care products in Europe. MDGN has been used in skin care products in the United States for the last 5 years. Contact allergy from MDGN has been reported from Europe. Objective: The purpose of this study was to determine the frequency of MDGN as a sensitizer in patients undergoing routine patch testing. Methods: We reviewed the results in 163 patients who underwent patch testing during a 4-month period to determine the number who had any reaction to MDGN at two different concentrations (0.2% and 0.5%). Tests were graded with the use of the North American Contact Dermatitis Group criteria (0 to 3+), and readings were performed at 48 and 96 hours (all positive reactions were evaluated at a follow-up visit or by telephone interview). Results: In the 4-month period, 45 of the 163 patients showed some reaction (± to 3+) at one or more readings. Of these, the results for 23 patients were considered to be irritant false-positive reactions; for 3 patients, the results were classified as uncertain; and for 19 patients, the results were classified as allergic. Of these, the results for eight patients were of definite relevance; the results for five patients were of probable relevance, and the results for six patients were of doubtful relevance to the problem condition. Other positive patch tests to a variety of allergens were frequently seen in persons positive to MDGN. Conclusion: MDGN is a sensitizer in skin products and, with the increase of its use, should be considered in the patch test evaluation of patients with persistent dermatitis. Optimum patch test concentrations are yet to be determined. (J Am Acad Dermatol 1998;38:934-7.)

Le texte complet de cet article est disponible en PDF.

Plan


 Reprint requests: Joseph F. Fowler, MD, University of Louisville, Division of Dermatology, Department of Medicine, 310 E. Broadway, Louisville, KY 40202.
 0190-9622/98/$5.00 + 0   16/1/89785


© 1998  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 38 - N° 6

P. 934-937 - juin 1998 Retour au numéro
Article précédent Article précédent
  • Papular dermatitis (subacute prurigo, “itchy red bump” disease): Pilot study of phototherapy
  • Adele R. Clark, Joseph L. Jorizzo, Alan B. Fleischer
| Article suivant Article suivant
  • Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial
  • Jerry Bagel, W.Thomas Garland, Debra Breneman, Michael Holick, T.W. Littlejohn, David Crosby, Holly Faust, David Fivenson, Jean Nichols

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.